MYMD vs. NAVB, BMRA, TRIB, CDIO, OCX, XBIO, HOTH, HCTI, AVGR, and KTRA
Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Biomerica (BMRA), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), OncoCyte (OCX), Xenetic Biosciences (XBIO), Hoth Therapeutics (HOTH), Healthcare Triangle (HCTI), Avinger (AVGR), and Kintara Therapeutics (KTRA). These companies are all part of the "medical" sector.
Navidea Biopharmaceuticals (NYSE:NAVB) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
In the previous week, MyMD Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for MyMD Pharmaceuticals and 1 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 1.44 beat MyMD Pharmaceuticals' score of 0.00 indicating that MyMD Pharmaceuticals is being referred to more favorably in the news media.
Navidea Biopharmaceuticals and MyMD Pharmaceuticals both received 0 outperform votes by MarketBeat users.
MyMD Pharmaceuticals has lower revenue, but higher earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Navidea Biopharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500.
0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 2.6% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
MyMD Pharmaceuticals' return on equity of 0.00% beat Navidea Biopharmaceuticals' return on equity.
Summary
MyMD Pharmaceuticals beats Navidea Biopharmaceuticals on 7 of the 11 factors compared between the two stocks.
Get MyMD Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MyMD Pharmaceuticals Competitors List
Related Companies and Tools
